2754 results about "CITRATE ESTER" patented technology

The invention discloses nutritional potato chips and a preparation method thereof. The nutritional potato chips are characterized by being prepared from the following raw materials in parts by weight: 90-100 parts of potatoes, 25-30 parts of rye flour, 3-4 parts of salt, 4-5 parts of oligosaccharide, 1-2 parts of zinc citrate, 8-10 parts of lily mayonnaise, 10-11 parts of almond, 11-12 parts of peanut, 12-13 parts of sesame, 1-2 parts of burdock, 1.5-1.8 parts of lophatherum gracile, 0.8-1.5 parts of tangerine peel, 1.5-2 parts of cassia seed, 1-1.5 parts of angelica, 2-2.5 parts of broadbean flower, 2-3 parts of apple blossom, 2-3 parts of stellaria media and 3-5 parts of rapeseed oil. The nutritional potato chips have superior flavor, are crisp, refreshing, scientific in proportion of all the ingredients and rich in nutrition, and have the effects of dispelling wind and heat, regulating qi, strengthening spleen, drying dampness, eliminating phlegm, replenishing blood, improving eyesight, cooling blood, detoxifying, maintaining beauty and keeping young.

A device for treating blood by extracorporeal circulation comprising a filter having a first chamber and a second chamber separated by a semi-permeable membrane. The device has an arterial line connected to the first chamber of the filter, a venous line issuing from the first chamber of the filter, a channel used for pre-infusion of a substance for regional anticoagulation and linked to the arterial line, a purge channel issuing from the second chamber of the filter, and an air separator on the venous line. The device also includes a line for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood downstream of the air separator, the post-infusion line being configured immediately upstream of an air detector.

The present invention is directed to a novel poly(diol citrates)-based nanocomposite materials created using completely biodegradable and biocompatible polymers that may be used in tissue engineering. More specifically, the specification describes methods and compositions for making and using nanocomposites comprised of citric acid copolymers and polymers including but not limited to poly(L-lactic acid) (PLLA) and poly(lactic-co-glycolic acid) (PLGA).

The decomposer film product has a polymeric decomposer layer, a cover layer for protecting the decomposer film from the surroundings and a releasable support liner, which is removed prior to use. The polymeric decomposer film contains a water-soluble or water-insoluble polymeric adhesive material and a decomposition accelerator, which acts to decompose an effective ingredient, such as a steroid hormone, of a worn or unused transderamal patch, when the effective ingredient releasing layer of the patch adheres to the polymer film, so that the pharmaceutical effective ingredient comes into contact with the decomposition accelerator by diffusion. The decomposition accelerator includes a chemically oxidizing substance, preferably urea peroxide, manganese (III) acetate or iron (III) citrate. The water-insoluble polymeric adhesive material is preferably an acrylates adhesive. The water-soluble polymeric adhesive material is preferably polyvinyl alcohol, polyvinyl pyrrolidone, a cellulose derivative or a polyacrylic acid.

A novel edible polymer based film dosage form manufactured using natural, synthetic, semisynthetic, pharmaceutically acceptable polymers addressing the issues of swallowing difficulties (Dysphagia and Dynaphagia), of tablet or capsule dosage forms and handling and storage difficulties associated with liquid dosage forms, that also includes materials such as emulsifying agents, suspending agents, buffering agents, effervescence agents, colorants, flavorants, sweeteners and specified amounts of bioactive agents, for erectile dysfunction. A flexible film dosage form containing sildenafil citrate, tadalafil or Vardenafil is presented. The film system is enabled to be used in various applications such as oral, mucosal and external environments.

The present invention is directed to a novel poly(diol citrates)-based coating for implantable devices. More specifically, the specification describes methods and compositions for making and using implantable devices coated with citric acid copolymers or citric acid copolymers impregnated with therapeutic compositions and/or cells.

Compositions containing strontium fortified calcium nanoparticles and/or microparticles, and methods of making and using thereof are described herein. The strontium fortified calcium compounds contain calcium ions, calcium atoms, strontium ions, strontium atoms, and combinations thereof and one or more anions. Exemplary anions include, but are not limited to, citrate, phosphate, carbonate, and combinations thereof. The particles can be formulated for enteral or parenteral administration by incorporating the particles into a pharmaceutically carrier. The compositions can further contain one or more active agents useful for bone diseases or disorders, such as vitamin D, growth factors, and combinations thereof. The compositions can be used to treat or prevent one or more bone diseases or disorders of the bone, such as osteoporosis. Alternatively, the particles can be coated onto a substrate, such as the surface of an implant. The coatings can be used to improved biocompatibility of the implant, prevent loosening of the implant, reducing leaching of metal ions from metallic implants, and reduce corrosion. The coatings can be applied to the substrate using a variety of techniques well known in the art. In one embodiment, the coating is applied using electrophoretic deposition. The use of nano- and/or microparticles that provide high surface area helps to improve interfacial strength between the coating and the implant, which allows for the use of lower sintering temperatures. Lowering sintering temperatures minimizes or prevents thermal decomposition of the coating material and/or degradation of the implant material.

Personal care and home care compositions are disclosed, which include silver dihydrogen citrate. The inventive compositions advantageously take the form of suspensions, pastes, liquids and gels. The inventive compositions also optionally comprise additional ingredients, and are therefore suitable for a wide variety of personal, home and industrial care purposes.

Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactatates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed.

The present invention relates to a preparation method of carbon quantum dots with adjustable fluorescence colors, and belongs to the technical field of nanometer materials. According to method, citric acid or a citrate is adopted as a carbon source, a nitrogen-containing compound is adopted as a nitridation agent, hydrogen peroxide is adopted as an oxidant, a hydrothermal synthesis method is adopted to obtain an aqueous solution of carbon quantum dots emitting blue or green fluorescence under ultraviolet light excitation, reaction conditions are easily controlled, and the method is suitable for scale production. The prepared carbon quantum dots have advantages of adjustable fluorescence color, high yield, high quantum efficiency, good result reproducibility and the like, wherein the product can be directly used for tumor cell labeling and live cell imaging labeling. According to the present invention, only the one reactant is required, the raw materials are easily-available and non-toxic, the production process does not require special protection, the reaction condition is easily controlled, and the obtained carbon quantum dots have advantages of high yield, high quantum efficiency, good result reproducibility and the like; and the method has characteristics of high yield, simple preparation process, low cost, easy scale production and the like.

The invention relates to a preparation method of a biological preservative. As known to all, along with the rapid development of the society, chemical preservatives have been used in food, have strong impact on food safety and endanger the health of consumers, therefore, the use of preservatives causes great concern of government departments and consumers. According to the biological preservative, natural plants and microbial antibiotic substances are used as base materials, for example, the biological preservative is prepared by mixture of carboxymethyl chitosan, xylooligosaccharide, nisin from lactic streptococci, acetic acid, lactobacillus reuteri, pediococcus acidilactici, calcium citrate, ionized calcium, lactic acid, plant essential oil and water. The biological preservative can inhibit growth of harmful microorganisms by antagonistic and competitive inhibition effects among different microorganisms and produce extracted and separated components of antibacterial active ingredients having antifungal and antibacterial functions in normal growth and metabolism processes, thereby achieving antiseptic and fresh-keeping effects.

Methods and compositions of the invention employ acetylcholinesterase (ACE) inhibitors to prevent and treat diseases and other disorders of the central nervous system (CNS), including Alzheimer's disease. ACE inhibitors are administered for targeted delivery to the CNS, for example by intranasal delivery. The methods and compositions of the present invention yield therapeutic concentrations of ACE inhibitors in a CNS tissue or compartment without the attendant disadvantages, risks and side effects of oral or injection delivery. Exemplary ACE inhibitors for use within the invention include galantamine and various salts and derivatives of galantamine. Carboxylate salts of galantamine (e.g., galantamine gluconate, galantamine lactate, galantamine citrate and galantamine glucarate) described herein exhibit a significant increase in solubility compared to other forms of galantamine, such as galantamine hydrobromide.

An improved process of coating tacky or soft polymer pellets to maintain a free-flowing property, uses a liquid binder, in conjunction with an anti-tack or partitioning powder such as talc to prevent aggregation during storage. The binder is a non-volatile material such as an oil or plasticizer including triglycerides, mono-/di-glycerides, acetylated mono-/di-glycerides, fatty acids, epoxidized triglycerides, phthalates, benzoates, sebacates, lactates, citrates, mineral oils etc. Applications of this process include chewing gum bases, hot-melt adhesives, sealants, rubber masterbatches, powdered rubber, and other soft and tacky polymer materials.

The invention discloses an ultrafine lead oxide prepared by using a waste lead plaster and a preparation method thereof. The preparation method comprises the following steps of: carrying out desulphurization process by mixing the waste lead plaster with an aqueous solution containing a composite desulfurizer for reaction; carrying out filtration to remove the desulphurization filtering solution to obtain the desulfurated lead plaster (filter residue); carrying out a leaching and crystal transformation process by adding a citric acid solution and a reducing agent into the desulfurated lead plaster obtained in the process, and carrying out filtration, washing, and drying to obtain the lead citrate after the desulfurated lead plaster reacts with the citric acid solution; carrying out a roasting process by roasting the lead citrate to obtain the ultrafine lead oxide. According to the preparation method disclosed by the invention, the ultrafine lead oxide is prepared from the waste lead storage lead plaster; a two-step leaching process is adopted; the filtering solution is simple in ingredient and can be recycled; a side product is recycled from the desulphurization solution. The preparation method disclosed by the invention is low in energy consumption, simple in equipment, high in lead recycling rate, and high in ultrafine lead product quality, and has the characteristics of good resource recycling effect, environmentally-friendly and pollution-free production process, and capability of clean production.

A method of characterizing a multi-component mixture for use in a bioprocess operation that includes providing a multi-component mixture standard with pre-determined amounts of known components; performing a Raman Spectroscopy analysis on the multi-component mixture standard; providing a multi-component test mixture from the bioprocess operation; performing a Raman Spectroscopy analysis on the multi-component test mixture; and comparing the analysis of the multi-component mixture standard and the multi-component test mixture to characterize the multi-component test mixture. In one embodiment, the multi-component mixture standard and the multi-component test mixture both comprise one or more of, at least two, at least three of, or each of, a polysaccharide (e.g. sucrose or mannitol), an amino acid (e.g., L-arginine, L-histidine or L-ornithine), a surfactant (e.g. polysorbate 80) and a pH buffer (e.g., a citrate formulation).

The invention relates to a biological agent against crucifer club root and application thereof, belonging to the technical field of bio-pesticide. The strain for production is Bacillus subtilis XF-1, whose preserving number is CGMCC NO.2357. The stain has the characteristics as follows: (1) the primary colony on the LB culture substrate is white and round having a wet surface; the later colony is light yellow having uneven edge with dry and crimple surface; observed from the microscope, the strain is short-bar shaped and movable with spore, peritricha and dimension of 0.7 - 0.8 * 2.0-2.4 mum; (2) the strain is Gram-positive and aerobic and makes use of glycogen, sugar, citrate, gelatin hydrolysate, starch and casein, but does not make use of cellulose, tyrosine and catalase positive; (3) the stain has the function of sterilization, disease prevention, and yield improvement. The embodiment of the invention is as follows: using the test tube of Bacillus subtilis XF-1 stain, shake cultivation, and culture solution for fermentation to prepare biological agent, then applying the biological agent to the rhizosphere soil of crucifer crops, thereby having good effect in preventing and treating, and simple production.

An antimicrobial and chemical deactivating composition for use in a liquid medium or for incorporation into a coating, structural plastic materials, thin microporous membranes, textiles and sponges. The composition includes macrosize or submicron particles of silver, platinum with silver and their salts with parabens, oxide, salicylate, acetate, citrate, benzoate and phosphate along with copper and zinc salts of the same.

Compositions comprising silver dihydrogen citrate in combination with a second antimicrobial compound are provided. The second antimicrobial compound may be quaternary ammonia, an oxidizer or a halogen species, such as chlorine, bromine or iodine. Methods of using the antimicrobial composition provide superior antimicrobial effects.

The blood collection, processing and transfer by separation of discrete components containing additional citrate (at least about trisodium citrate 9% w/v) in one or other of collection or processing bag provides for enhanced yield and purity of cryoprecipitate. Inhibiting the activation or denaturation of blood components including blood cells and plasma proteins and with the removal of the activated and denatured components thereby improving safety and efficacy of end products. The inventive process is particularly suited to an improved extraction process to yield concentrated clotting factors from single donors or limited pools without use of chromatography. Following extraction the remaining cryoprecipitate can advantageously be formed into a fibrin fabric used in surgeries and in the treatment of wounds